干扰素治疗的多发性硬化症中的趋化因子受体CCR5
Chemokine receptor CCR5 in interferon-treated multiple sclerosis.
作者信息
Sellebjerg F, Kristiansen T B, Wittenhagen P, Garred P, Eugen-Olsen J, Frederiksen J L, Sørensen T L
机构信息
The MS Clinic, Department of Neurology, Glostrup Hospital, University of Copenhagen, 57 Nordre Ringvej, DK-2600 Glostrup, Denmark.
出版信息
Acta Neurol Scand. 2007 Jun;115(6):413-8. doi: 10.1111/j.1600-0404.2007.00826.x.
OBJECTIVE
To study the relationship between CC chemokine receptor CCR5 expression and disease activity in multiple sclerosis (MS) patients treated with beta-interferon (IFN-beta).
METHODS
The CCR5 Delta32 allele and a CCR5 promoter polymorphism associated with cell surface expression of CCR5 were analyzed in 109 patients with relapsing-remitting MS treated with IFN-beta who were followed clinically for 1 year. Cellular CCR5 expression was measured by flow cytometry.
RESULTS
Patients with MS had a higher percentage of CCR5-positive monocytes than healthy controls. Increased monocyte expression of CCR5 correlated weakly with an increased short-term relapse risk but there was no relationship between CCR5 Delta32 allele and CCR5 promoter polymorphism genotypes and relapse risk.
CONCLUSIONS
The results do not support a major role of CCR5 in the pathogenesis of relapses in MS patients treated with IFN-beta, but it is possible that monocyte CCR5 expression may be used as a marker of disease activity.
目的
研究接受β-干扰素（IFN-β）治疗的多发性硬化症（MS）患者中CC趋化因子受体CCR5表达与疾病活动度之间的关系。
方法
对109例接受IFN-β治疗的复发缓解型MS患者进行CCR5 Δ32等位基因及与CCR5细胞表面表达相关的CCR5启动子多态性分析，并对其进行为期1年的临床随访。通过流式细胞术检测细胞CCR5表达。
结果
MS患者CCR5阳性单核细胞的百分比高于健康对照。CCR5单核细胞表达增加与短期复发风险增加呈弱相关，但CCR5 Δ32等位基因及CCR5启动子多态性基因型与复发风险之间无关联。
结论
结果不支持CCR5在接受IFN-β治疗的MS患者复发发病机制中起主要作用，但单核细胞CCR5表达有可能用作疾病活动度的标志物。
Zotero 插件